Patents Assigned to Quixgen, Inc.
  • Spirolactone compounds
    Patent number: 12102633
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 3, 2023
    Date of Patent: October 1, 2024
    Assignee: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Spirolactone Compounds
    Publication number: 20230355609
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: November 9, 2023
    Applicant: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Spirolactone compounds
    Patent number: 11541046
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 3, 2023
    Assignee: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Novel Spirolactone Compounds
    Publication number: 20210145822
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 20, 2021
    Applicant: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang